(Q46876508)

26 December 2017

title

Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome (English)

1 reference

26 December 2017

1 reference

I Mertens

1

1 reference

26 December 2017

A Verrijken

2

1 reference

26 December 2017

J J Michiels

3

1 reference

26 December 2017

M Van der Planken

4

1 reference

26 December 2017

J B Ruige

5

1 reference

26 December 2017

L F Van Gaal

6

1 reference

26 December 2017

language of work or name

English

0 references

publication date

3 January 2006

1 reference

26 December 2017

International Journal of Obesity

published in

1 reference

26 December 2017

volume

30

1 reference

26 December 2017

issue

8

1 reference

26 December 2017

page(s)

1308-1314

1 reference

26 December 2017

American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Endothelial dysfunction and inflammation-is there a link?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Inflammation and thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Obesity, haemostasis and the fibrinolytic system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Assessment of fat-free mass using bioelectrical impedance measurements of the human body.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Changes in fat-free mass during weight loss measured by bioelectrical impedance and by densitometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Comment on the provisional report from the WHO consultation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Impact of weight loss on the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJO.0803189

7 January 2021

Identifiers

DOI

10.1038/SJ.IJO.0803189

1 reference

26 December 2017

1 reference

26 December 2017